Sun, Aug 07, 2016 - Page 5 News List

Engineered mosquitoes closer in US

Reuters, CHICAGO

US health regulators have cleared the way for a trial of genetically modified mosquitoes in Florida that could reduce mosquito populations, potentially offering a new tool to fight the local spread of Zika and other viruses.

The US Food and Drug Administration (FDA) on Friday said that a field test of Intrexon Corp’s genetically engineered mosquitoes would not have a significant effect on the environment. The announcement came as Florida officials grapple with the first cases of local Zika transmission in the continental US.

Florida health authorities have identified 16 Zika cases spread by local mosquitoes and are ramping up aerial pesticide spraying of a Miami neighborhood where all of the people are believed to have been infected.

Pregnant women are most at risk from Zika, which can cause a rare birth defect in fetuses called microcephaly. The Zika outbreak was first detected last year in Brazil and has spread rapidly in the Americas.

Intrexon’s Oxitec unit has been working for years to start a trial in the Florida Keys to assess the effectiveness of its mosquitoes to reduce levels of the insects that carry diseases, including Zika, dengue, Yellow Fever and chikungunya.

The Oxitec method involves inserting an engineered gene into male Aedes aegypti mosquitoes. When they mate with female mosquitoes in the wild, they produce offspring that cannot survive to adulthood.

The FDA has been reviewing Oxitec’s application for use of its technology as an investigatory new animal drug. Its environmental assessment helps clear the way for the company to begin a clinical trial in Key Haven, Florida, that would test whether the genetically modified mosquitoes will suppress the wild populations over time.

Results of that trial would be used to support approval of the company’s technology, a process that could take more than a year. Similar testing in Brazil, Panama and the Cayman Islands have shown that the Oxitec mosquitoes can reduce local A aegypti populations by more than 90 percent.

To begin the trial, the company must first await the results of a vote in the Nov. 8 general election seeking community approval.

Oxitec chief executive Hadyn Parry said in a conference call that the vote is non-binding and the decision about whether to proceed is up to the Florida Keys Mosquito Control District, the local body responsible for mosquito control.

Community support in the vote is not guaranteed.

In Key Haven, a suburb of large, waterfront homes near Key West where the trial is slated to take place, yard signs have popped up declaring “no consent” to the release of genetically modified mosquitoes.

Kathryn Watkins, a Key Haven resident recruited by trial opponents, is seeking election to the board overseeing the Florida Keys Mosquito Control District.

“It just has everyone scared,” Watkins said, adding that local residents see themselves as unwilling test subjects.

“The genetically modified male has to mate with a wild female, and the wild female has to bite us in order to lay eggs,” she said.

“They are using us in this trial without consent,” she added.

As his company awaits the vote, Parry said he intends to ask the FDA for an emergency-use authorization that would make the product available to help battle Zika in the US.

The FDA has approved several diagnostic products under this designation.

This story has been viewed 2298 times.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top